trβ

TR antagonist 1 is a highly potent thyroid hormone receptor (TR) antagonist (IC50 of 36 and 22 nM for TRα and TRβ, respectively) that can be used to study diseases caused by endocrine abnormalities.

Liothyronine Sodium is the sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium (3,3',5-Triiodo-L-thyronine sodium) binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).

TRβ agonist 3 (Compound 3) is a potent TRβ agonist and a potential TRβ-selective thyromimetic. In vitro studies show that TRβ agonist 3 reduces lipid accumulation in HepG2 cells and promotes lipolysis [1].

TRβ agonist 2 (Compound 1) is a highly potent TRβ agonist that effectively reduces lipid accumulation in HepG2 cells and promotes lipolysis, offering comparable effects. With its promising attributes, TRβ agonist 2 emerges as a potential thyromimetic selectively targeting TRβ [1].

TRβ Agonist 1, a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, demonstrates an EC50 value of 21 nM. It is useful in the research of dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) [1].

Liothyronine (Tresitope) is a synthetic and highly active thyroid hormone that acts as an effective agonist of TRα and TRβ (Ki = 2.33 nM for both hTRα and hTRβ). It activates the TRβ1 receptor, promotes the metabolism of carbohydrates, proteins, and fats, accelerates the oxidative processes in tissue cells, maintains basal metabolic rate, and supports normal growth and development. Liothyronine can be used to induce hyperthyroidism models.

Triiodothyronine Sulfate is a prodrug to the Conventional Hormone Therapy of Hypothyroidism. Triiodothyronine sulfate is the main metabolite of thyroid hormone triiodothyronine (T3). Triiodothyronine is an active form of thyroid hormone bind to β1 thyroid

GC 14 is a selective thyroid hormone receptor antagonist with IC50 values of 200 nM for hTRα and 35 nM for hTRβ.

NXT629 is a selective and highly efficient PPAR-α antagonist with anticancer activity. It inhibits PPARδ, PPARγ, Erβ, GR, and TRβ and can be used in research on ovarian cancer and melanoma.

3,5-Diiodothyropropionic acid (C082182) is a thyroid hormone analog. It induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (Ka: 2.40 M and 4.06 M for TRα1 and TRβ1).

Sob-AM2 is an effective substrate targeting the fatty acid amide hydrolase (FAAH) expressed in the brain, with a Km of 1.3 μM. It delivers higher concentrations of Sobetirome to the central nervous system at minimal peripheral systemic doses, thereby activating the central thyroid hormone receptor β (TRβ).

THR-β agonist 8 (Compound 1) is an orally active agonist for both TRα and TRβ. It holds potential for research into thyroid hormone-related diseases.

MLS000389544 is a selective and potent thyroid hormone receptor β (TRβ) antagonist with a methylsulfonyl nitrobenzoic acid structure. It effectively inhibits the interaction between TRβ and steroid receptor coactivator 2 (SRC2).

Sobetirome (IACS-010759) is a selective agonist of thyroid hormone receptor β (TRβ) and binds selectively to TRβ-1 (EC50: 0.16 μM).

Eprotirome (KB2115), a synthetic thyroid hormone mimetic, is a thyroid hormone receptor agonist.

Liothyronine sodium hydrate (Triiodothyronine sodium hydrate) is a TRα and TRβ agonist and a thyroxine analog with anticancer and antitumor activities. It can be used to study hypothyroidism, stroke and cognitive dysfunction.